N4 Pharma Plc (LON:N4P – Get Free Report) shares traded up 11.6% during trading on Monday . The stock traded as high as GBX 0.60 ($0.01) and last traded at GBX 0.58 ($0.01). 985,275 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 3,346,229 shares. The stock had previously closed at GBX 0.52 ($0.01).
N4 Pharma Stock Performance
The stock has a market capitalization of £2.48 million, a price-to-earnings ratio of -1.66 and a beta of -0.37. The firm has a 50-day moving average of GBX 0.62 and a 200 day moving average of GBX 0.61.
N4 Pharma Company Profile
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
Read More
- Five stocks we like better than N4 Pharma
- How to Calculate Stock Profit
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- Following Congress Stock Trades
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- Growth Stocks: What They Are, Examples and How to Invest
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
